Incidence rates of metastatic prostate cancer continue to climb in the United States, a trend that coincides temporally with recommendations against prostate cancer screening from the US Preventive Services Task Force (USPSTF), investigators reported at the 22nd annual meeting of the Society of Urologic Oncology.
The USPSTF recommended against routine PSA-based prostate cancer screening initially for men older than 75 years in 2008 and for all men in 2012.
The latest findings are from an analysis of data from the recently released Surveillance, Epidemiology, and End Results (SEER) 18 registry incidence data (2004 to 2018).
Among men aged 45 to 74 years, the incidence rate of metastatic prostate cancer remained stable from 2004 to 2010, then rose significantly by 5.3% annually from 2010 to 2018, according to Giovanni Cacciamani, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues. Among men aged 75 years or older, the incidence rate decreased by 1.5% annually from 2004 to 2011 and then increased by 6.5% annually from 2011 to 2018.
The increasing trend in metastatic prostate cancer incidence were especially pronounced among non-Hispanic White men, according to the investigators.
Desai M, Cacciamani G, Gill K, et al. Incidence of metastatic prostate cancer in the United States continues to increase. Presented at the 22nd annual meeting of the Society of Urologic Oncology, December 1-3, 2021. Poster 215.
This article originally appeared on Renal and Urology News